slides · global inventory
Quote
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 10,645
Current window 8,191-8,220
Pages 355
Rows per page 30
Component
8,191-8,220 of 10,645
228
The slide uses a Q&A transcript format to highlight the alleged suppression of negative clinical trial results.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
234
The slide uses a long, narrative-style headline that summarizes the ex-employee's critique, followed by a highlighted block quote.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
236
The slide uses a direct quote from an ex-employee to undermine the clinical value proposition of the drug.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
241
The slide uses a quote to establish credibility and validate the activist's research findings.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
243
The slide uses a Q&A format to validate the primary claim made in the headline.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
245
The slide uses a 'quote-summary' structure to undermine the company's launch narrative.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
253
The slide uses a quote to undermine the credibility of the company's clinical trial data by highlighting the difference between controlled trial environments and real-world application.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
257
The slide uses a Q&A format to present expert testimony that undermines the value proposition of the drug Vykat.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
261
The slide uses a quote to highlight potential ethical or professional concerns regarding a physician's promotion of a drug.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
285
The slide uses a Q&A format to present expert opinion as evidence of safety risks.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
290
The slide uses a Q&A format to highlight allegations of 'artificial enrollment' and data manipulation.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
295
The slide uses a Q&A transcript format to highlight negative sentiment from a key opinion leader.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
306
The slide uses a Q&A format to present qualitative evidence from a trial investigator.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
307
The slide uses a Q&A format to highlight the investigator's skepticism.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
312
The slide uses a direct quote from an endocrinologist to cast doubt on the company's clinical data integrity.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
327
The slide uses a bolded summary paragraph at the top, followed by a detailed Q&A transcript with yellow highlighting on key quotes.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
328
The slide uses a Q&A transcript format to support the thesis that the competitor product is unnecessary or inferior.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
332
The slide uses a direct quote from an endocrinologist to undermine the primary endpoint of a clinical trial.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
338
The slide uses a Q&A transcript format to highlight potential misclassification of adverse events in a clinical trial.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
344
The slide uses a Q&A format to validate the expert's critique of the product's form factor.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
350
The slide presents a Q&A format highlighting expert skepticism regarding the drug's safety profile and market relevance.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
358
The slide uses a Q&A format to highlight skepticism among medical professionals regarding a drug's marketing presentation.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
363
The slide highlights a discrepancy between the company's sales pitch and clinical best practices as perceived by an expert.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
367
The slide highlights a direct contradiction between the company's marketing (Vykat) and expert clinical opinion.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
369
The slide highlights the endocrinologist's reluctance to prescribe the drug, noting that patient pressure was a primary driver for his involvement.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
379
The slide uses a direct quote from a pediatric endocrinologist to undermine the drug's clinical value.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
384
The slide uses a pull-quote style to highlight the expert's hesitation and lack of full support.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
385
The slide highlights a potential safety concern raised by an expert, specifically regarding pre-diabetic and obese patients.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
386
The slide presents a Q&A format where the expert questions the company's motives and the clinical rationale for their product.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
388
The slide uses a combination of summary text and direct interview transcripts to build a case against the drug's adoption.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit